Speaker: Maria-Victoria Mateos

0:11:10

María-Victoria Mateos, EHA 2020: The TOURMALINE-MM4 study

0:01:41

Key findings of the LocoMMotion study

0:01:49

The importance of MRD assessment in Myeloma with Prof. Mateos

0:03:38

A look into the future: CAR-T and bispecifics in myeloma

0:09:18

Advances in the clinical management of SM

0:02:19

ARROW: carfilzomib dosing in frail R/R multiple myeloma patients

0:03:17

LOCOMMOTION: analysis of SOC for R/R myeloma

0:02:10

Proteasome inhibitors-based combinations for elderly MM

0:00:56

Individualising treatment for elderly MM patients

0:04:07

Implementation of CAR T-cell therapy in myeloma: practical and patient-related aspects

0:01:52

The extension of survival at relapse

0:04:28

Cellular therapy: changing clinical practice for treatment of myeloma

0:03:55

Overview of the SIRIUS clinical trial in the treatment of multiple myeloma

0:01:37

Screening myeloma precursor conditions to predict progression

0:01:28

Evaluating next-generation immunotherapies in earlier lines of treatment in multiple myeloma

0:02:26

Early relapse: options for rescue

0:01:40

Risk-adapted management strategies for smoldering myeloma

0:01:51

Management of multiple myeloma in frail/elderly patients

0:02:15

Comparison of patient-reported outcomes from CARTITUDE-1 and LocoMMotion

0:03:59

Induction and front-line therapy for myeloma

0:01:40

Key topics from IMW 2019

0:11:36

An MRD discussion: when, who and how

0:04:08

Assessment and treatment of smouldering myeloma

0:02:14

The future role of transplantation in myeloma